Compositions and methods for preventing and/or treating filarial disease
AssigneesThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsEdward Elais Saul Mitre, Christopher Paul Morris, Alexander Francis Flynn, Thomas B. Nutman, Sasisekhar Bennuru
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT) or immunoglobulin I-set domain containing protein (Igl-DCP, also known as BMA-Lad-2). The inhibitors include those known to inhibit glucuronyltransferase enzyme activity as well as cell adhesion molecule inhibitors and antibodies specific for Igl-DCP and/or UGT.
Claims19
A method for preventing or treating a helminth disease in an animal in need thereof, which comprises:
- administering to the animal a composition comprising a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT), wherein the composition effectively kills adult helminths in the animal but not microfilariae, and the inhibitor of UDP-glucoronosyl transferase (UGT) is sulfinpyrazone or p-(di-n-propylsulphamyl)-benzoic acid (probenecid).
A method of killing adult helminths in an animal in need thereof, which comprises:
- administering to the animal a composition comprising an amount of an inhibitor of UDP-glucoronosyl transferase (UGT), wherein the inhibitor of UGT is sulfinpyrazone or p-(di-n-propylsulphamyl)-benzoic acid (probenecid), wherein the amount is effective to kill adult helminths in the animal, and wherein the adult helminths are not of the species Haemonchus contortus.
Dependencies are inferred from the claim text.